演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

一次治療でCapecitabine+Bevacizumab(Cape-Bev)療法を使用した21例の検討

演題番号 : P18-4

[筆頭演者]
演者)山田 泰史:1 
[共同演者]
横溝 肇:1、岡山 幸代:1、前田 裕之:1、井田 在香:1、佐竹 昌也:1、矢野 有紀:1、浅香 晋一:1、碓井 健文:1、塩澤 俊一:1、吉松 和彦:1、島川 武:1、勝部 隆男:1、加藤 博之:2、成高 義彦:1

1:東京女子医科大学東医療センター・外科、2:東京女子医科大学東医療センター・検査科

 

[Background] Capecitabine+Bevacizumab (Cape+Bev) therapy is recommended as a first-line treatment not only for patients for whom intensive therapy are appropriate but even for those to whom they do not apply, in the Japanese Society for Cancer of the colorectal guidelines 2016 as a choice of treatment for unresectable progressive recurrent colorectal cancer. Nevertheless, there are not many reports collating Cape+Bev therapy in Japan.
[Methods] The subjects consisted of 21 cases receiving Cape+Bev therapy as a first-line treatment at our department for unresectable progressive recurrent colorectal cancer between April 2011 and April 2018.
[Findings] The subjects were 15 males and 6 females with a median age of 81 years. The reasons for choosing the regimen were as follows: 7 cases of poor performance status (PS), 5 cases of advanced age, 4 cases of impaired kidney function, and 5 cases at the behest of the patient and their families. There were no cases of treatment-related death. The median value for the total number of courses was 7 courses (1-27 courses). To date, there have been 18 cases in which treatment was stopped, with the reasons as follows: PD in 10 cases, worsening PS in 2 cases, adverse events in 3 cases, and the behest of the patient in 2 cases, and 1 case shifted to curative resection was also observed. Seven cases of grade 3 or higher adverse events were observed, and there were 4 cases of proteinuria, 1 case of hand-foot syndrome, 1 case of elevated blood pressure, 1 case of anemia, and 1 case of a rise in serum creatinine values. The median value of progression-free survival after chemotherapy was 10.0 months, and the overall survival period after chemotherapy was 28.5 months.
[Interpretation] Cape+Bev therapy as a first-line treatment for unresectable progressive recurrent colorectal cancer shows comparatively favorable PFS even in the cases of poor PS and elderly patients, and can be favorably accepted from the viewpoint of adverse events.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る